JULIE GASTIER-FOSTER to Antineoplastic Agents
This is a "connection" page, showing publications JULIE GASTIER-FOSTER has written about Antineoplastic Agents.
Connection Strength
0.674
-
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018 04 03; 23(1):227-238.e3.
Score: 0.315
-
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. Cancer Discov. 2022 11 02; 12(11):2646-2665.
Score: 0.108
-
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
Score: 0.094
-
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood. 2015 Aug 20; 126(8):964-71.
Score: 0.065
-
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 01; 32(34):3874-82.
Score: 0.062
-
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell. 2016 Feb 08; 29(2):186-200.
Score: 0.017
-
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011 Jul 14; 118(2):243-51.
Score: 0.012